Meningococcal vaccine: Outbreaks, travel, and more

Hospital Pharmacy

Volumn 32, Issue 9, 1997, Pages 1219-1306

  Grabenstein, John D ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; RIFAMPICIN; SULFADIAZINE;

ANTIBIOTIC PROPHYLAXIS; BRAIN INFARCTION; DISEASE TRANSMISSION; EPIDEMIC MENINGITIS; HEARING IMPAIRMENT; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOTHERAPY; NEISSERIA MENINGITIDIS; PHARMACIST; REVIEW; SEIZURE; SERODIAGNOSIS; VACCINE PRODUCTION;

EID: 0030851710     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Feldman HA. Some recollections of the meningococcal diseases: The first Harry F. Dowling lecture. JAMA, 1972;220:1107-1112.
2. Gold R. Meningococcal disease in Canada: 1991-92. Can J Public Health. 1992;83: 5-8.
3. Hume SE. Mass voluntary immunization campaigns for meningococcal disease in Canada: Media hysteria. JAMA. 1992;267: 1833-1834,1837-1838.
4. Zollinger WD. Meningococcal meningitis. In: Cryz SJ Jr., ed. Vaccines and Immunotherapy. New York, NY: Pergamon Press; 1991, 113-126.
5. Lepow ML. Meningococcal vaccines. In: Plotkin SA, Mortimer EA Jr. Vaccines. 2nd ed. Philadelphia, PA: W. B. Saunders; 1994:503-515.
6. Benenson AS, ed. Control of Communicable Diseases Manual. 16th ed. Washington, DC: American Public Health Association; 1995, 303-307.
7. Grabenstein JD. ImmunoFacts: Vaccines and Immunologic Drugs. St. Louis: Facts and Comparisons; May 1997.
8. Advisory Committee on Immunization Practices. Control and prevention of meningococcal disease. MMWR. 1997; 46(RR-5):1-10.
9. Advisory Committee on Immunization Practices. Control and prevention of serogroup C meningococcal disease: Evaluation and management of suspected outbreaks. MMWR. 1997;46(RR-5):13-21.
10. Meningococcal Disease Surveillance Group. Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis. 1976;134: 201-204.
11. Riewerts Eriksen NH, Espersen F, Laursen L, Skinhoj P, Hoiby N, Lind I. Nosocomial outbreak of group C meningococcal disease. BMJ. 1989;298:568-569.
12. Grabenstein JD, Cecil WJ, Weber DJ. Prevention and management of meningococcal infections in healthcare facilities [submitted manuscript].
13. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: An emerging threat. JAMA. 1995;273:383-389.
14. Casadevall A. Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis. 1996;2:1-11.
15. Hoyne AL. Intravenous treatment of meningococcic meningitis with meningococcus antitoxin. JAMA. 1936;107: 478-481.
16. Flexner S. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med. 1913;17:553-576.
17. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus: 4. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med. 1969; 129:1367-1383.
18. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970; 282:417-420.
19. Advisory Committee on Immunization Practices. Recommendations of the Advisory Committee on Immunization Practices: Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR. 1993;42(RR-4):1-18.
20. American College of Physicians. Guide for Adult Immunization. 3rd ed. Philadelphia, PA: American College of Physicians; 1994, 49-55.
21. Ruben FL, Hankins WA, Zeigler Z, Norden CW, Harrison A, Winkelstein A, Herrmann DJ. Antibody responses to meningococcal polysaccharide vaccine in adults without a spleen. Am J Med. 1984;76: 115-121.
22. Khoo SH, St. Clair-Roberts J, Mandal BK. Safety and efficacy of combined meningococcal and typhoid vaccine. BMJ. 1995; 310:908-909.
23. Travis S. Control of meningococcal disease [letter]. BMJ. 1989;298:1033.
24. Canadian Laboratory Centre for Disease Control. Guidelines for control of meningococcal disease. Can Comm Dis Rep. 1994;20:17-27.
25. Stuart JM, Monk PN, Lewis DA, Constantine C, Kaczmarski EB, Cartwight KAV. Management of clusters of meningococcal disease. Comm Dis Rep Rev. 1997;7:3-6.
26. Jackson LA, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Publ Health. 1995;85:843-845.
27. Anderson EL, Bowers T, Mink CM, Kennedy DJ, Belshe RB, Harakey H, Pais L, Holder P, Carlone GM. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun. 1994;62;3391-3395.
28. Lieberman JM, Chiu SS, Wong VK, Partridge S, Chang SJ, Chiu CY, Gheesling LL, Carlone GM, Ward JI. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children: A randomized controlled trial. JAMA. 1996;275:1499-1503.
29. Romero JD, Outschoorn IM. Current status of meningococcal group B vaccine candidates: Capsular or noncapsular? Clin Microbiol Rev. 1994;7:559-575.
30. Boslego JB, Garcia J, Cruz C. Efficacy, safety, and immunogenicity of a meningococcal vaccine group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine. 1995;13:821-829.
31. Thomson APJ, Hayhurst GK. Press publicity in meningococcal disease. Arch Dis Child. 1993;69:166-169.
32. Peltola H. Early meningococcal disease: Advising the public and the profession. Lancet. 1993;342:509-510.